Prorenin-Induced Myocyte Proliferation
No Role for Intracellular Angiotensin II


Abstract—Cardiomyocytes bind, internalize, and activate prorenin, the inactive precursor of renin, via a mannose 6-phosphate receptor (M6PR)–dependent mechanism. M6PRs couple directly to G-proteins. To investigate whether prorenin binding to cardiomyocytes elicits a response, and if so, whether this response depends on angiotensin (Ang) II, we incubated neonatal rat cardiomyocytes with 2 nmol/L prorenin and/or 150 nmol/L angiotensinogen, with or without 10 nmol/L M6P, 1 μmol/L eprosartan, or 1 μmol/L PD123319 to block M6P and AT1 and AT2 receptors, respectively. Protein and DNA synthesis were studied by quantifying [3H]-leucine and [3H]-thymidine incorporation. For comparison, studies with 100 nmol/L Ang II were also performed. Neither prorenin alone, nor angiotensinogen alone, affected protein or DNA synthesis. Prorenin plus angiotensinogen increased [3H]-leucine incorporation (+21±5%, mean±SEM, P<0.01), [3H]-thymidine incorporation (+29±6%, P<0.01), and total cellular protein (+14±3%, P<0.01), whereas Ang II increased DNA synthesis only (+34±7%, P<0.01). Eprosartan, but not PD123319 or M6P, blocked the effects of prorenin plus angiotensinogen as well as the effects of Ang II. Medium Ang II levels during prorenin and angiotensinogen incubation were <1 nmol/L. In conclusion, prorenin binding to M6PRs on cardiomyocytes per se does not result in enhanced protein or DNA synthesis. However, through Ang II generation, prorenin is capable of inducing myocyte hypertrophy and proliferation. Because this generation occurs independently of M6PRs, it most likely depends on the catalytic activity of intact prorenin in the medium (because of temporal prosegment unfolding) rather than its intracellular activation. Taken together, our results do not support the concept of Ang II generation in cardiomyocytes following intracellular prorenin activation. (Hypertension. 2002;39[part 2]:573-577.)

Key Words: myocytes • renin • insulin growth factor • receptors, angiotensin

Cardiac angiotensin synthesis depends on renin of renal origin, both under normal and pathological conditions.1–4 Circulating kidney-derived renin diffuses into the cardiac interstitial space and/or may bind to renin receptors.7–9 In addition, the heart may sequester prorenin, the precursor of renin, from the circulation. Prorenin could contribute to angiotensin generation at cardiac tissue sites, either because of its inherent catalytic activity, which is the consequence of temporal prosegment unfolding, or following its local conversion to renin. In support of this concept, we have recently demonstrated that cardiac myocytes and fibroblasts are capable of binding and internalizing recombinant human renin and prorenin via mannose 6-phosphate/insulin-like growth factor II (M6P/IGFII) receptors, and that prorenin following its internalization is rapidly activated to renin by proteolytic cleavage of the prosegment.12,13

Recombinant as well as native human renin and prorenin contain the M6P signal that is required to bind to M6P/IGFII receptors.14–16 These receptors also contain binding domains for IGFII and retinoic acid,17,18 and binding of the latter agonists to M6P/IGFII receptors results in second messenger activation and growth inhibition, respectively.19,20 Moreover, proliferin, which, similar to (pro)renin, binds to M6P/IGFII receptors via its M6P group,21 has been reported to induce endothelial cell chemotaxis via these receptors in a G-protein- and mitogen-activated protein kinase-dependent manner.22 In this respect, it is of interest to note that renin binding to mesangial cells resulted in enhanced 3H-thymidine incorporation and plasminogen-activator inhibitor-1 (PAI-1) release, without intermediate angiotensin generation.9

M6P/IGFII receptor-mediated accumulation of renin and activated prorenin in cardiac cells may result in intracellular angiotensin generation, and such intracellular angiotensin synthesis could underlie the stretch-mediated release of angiotensin II (Ang II) that has been demonstrated in myocytes.23,24 However, to allow intracellular Ang II synthesis, the intracellular presence of angiotensinogen and ACE is also required, and in previous studies we were unable to detect angiotensinogen synthesis by cardiomyocytes.25

Received September 23, 2001; first decision November 2, 2001; revision accepted November 12, 2001.
From the Cardiovascular Research Institute COEUR, Departments of Pharmacology (J.J.S., M.M.E.D.v.d.E., P.R.S., A.H.J.D.), Internal Medicine (J.J.S., M.M.E.D.v.d.E., M.A.D.H.S.), and Biochemistry (J.M.J.L.), Erasmus University Medical Center Rotterdam, The Netherlands.
Correspondence to A.H.J. Danser, PhD, Department of Pharmacology, Room EE1418b, Erasmus University Rotterdam, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands. E-mail danser@farma.fgg.eur.nl

Hypertension is available at http://www.hypertensionaha.org

573
In the present study, we set out to investigate whether prorenin binding, internalization, and activation by neonatal rat cardiomyocytes results in a cellular response, either directly (without intermediate Ang II generation), via binding to M6P/IGFII receptors, or indirectly, via the generation of Ang II and subsequent AT receptor activation. We measured protein and DNA synthesis following incubation of cells with recombinant human prorenin with or without angiotensinogen. Experiments were repeated in the presence of M6P, eprosartan, and PD123319, to antagonize M6P/IGFII, AT1, -AT1, and AT2 receptors, respectively. For comparison, we also studied the effect of Ang II in the presence and absence of these antagonists. Finally, we investigated Ang I and II generation during incubation of myocytes with prorenin and angiotensinogen, taking into consideration that prorenin itself displays catalytic activity (ie, without protegment cleavage).

**Methods**

**Cell Culture**

All experiments were performed according to the regulations of the Animal Care Committee of the Erasmus University Medical Center Rotterdam, in accordance with the “Guiding Principles” of the American Physiological Society.

Primary cultures of neonatal Wistar rat (Harlan) cardiomyocytes were prepared as previously described.12,13 Cells were seeded in noncoated 24-well plates (Corning Costar), giving a confluent monolayer of spontaneously beating myocytes at 1.5 x 10⁶ cells/cm² after a 24-hour incubation in 1.5 mL medium (consisting of DMEM and Medium 199 [4:1], supplemented with 5% fetal calf serum [Life Technologies], 5% horse serum [Sigma], 100 U/mL penicillin, and 100 mg/mL streptomycin [Roche]). Thereafter, cells were incubated for 48 hours in medium supplemented with 5% horse serum and for 24 hours in serum-free medium. Before the start of each experiment, cells were rinsed 3 times with 1 mL warm (37°C) phosphate-buffered saline. Next, myocytes were incubated for 24 hours at 37°C with 250 μL serum-free medium, supplemented with 1% bovine serum albumin (BSA), and containing 100 U/L (≈2 nmol/L) recombinant human prorenin (a kind gift of Dr S. Mathews, Hoffmann-LaRoche, Basel, Switzerland) and/or 150 nmol/L human angiotensinogen (Sigma) in the presence or absence of 10 nmol/L M6P, 1 μmol/L eprosartan, or 1 μmol/L PD123319. For comparison, experiments with 100 nmol/L Ang II (Bachem) were also performed. Cells incubated without prorenin, angiotensinogen, or Ang II served as control.

**Protein and DNA Synthesis**

Protein and DNA synthesis rates were determined in triplicate by quantifying [³H]-leucine and [³H]-thymidine incorporation during incubation of myocytes with prorenin and angiotensinogen, 2 nmol/L prorenin plus 150 nmol/L angiotensinogen, and 100 nmol/L angiotensin (Ang) II on total cellular protein content, total cellular DNA content, [³H]-leucine incorporation, and [³H]-thymidine incorporation in cardiomyocytes. Data are expressed as percentage change from control (mean±SEM of 8–16 experiments). PR indicates prorenin; Aog, angiotensinogen; *P<0.01 versus control.

**Angiotensin Generation**

Ang I and Ang II were undetectable in medium or cells under control conditions and following incubations with either prorenin alone or angiotensinogen alone. At 1 hour after the addition of 2 nmol/L prorenin combined with 150 nmol/L
Prorenin + Angiotensinogen

Figure 2. Effect of 2 nmol/L prorenin plus 150 nmol/L angiotensinogen on total cellular protein content, total cellular DNA content, [3H]-leucine incorporation, and [3H]-thymidine incorporation in cardiomyocytes in the presence of vehicle (none), the AT1 receptor antagonist eprosartan (Epro; 1 μmol/L), or the M6P/IGFII receptor antagonist PD123319 (1 μmol/L), or the M6P/IGFII receptor antagonist M6P (10 mmol/L). Data are expressed as percentage change from control (mean±SEM of 8 experiments). #P<0.05 versus none.

Prorenin + Angiotensinogen

Figure 3. Effect of 100 nmol/L Ang II on total cellular protein content, total cellular DNA content, [3H]-leucine incorporation, and [3H]-thymidine incorporation in cardiomyocytes in the presence of vehicle (none), the AT1 receptor antagonist eprosartan (Epro; 1 μmol/L), the AT2 receptor antagonist PD123319 (1 μmol/L), or the M6P/IGFII receptor antagonist M6P (10 mmol/L). Data are expressed as percentage change from control (mean±SEM of 8 experiments). #P<0.05, *P<0.01 versus none.

Discussion

Prorenin binding to M6P/IGFII receptors located on the cell surface of neonatal rat cardiomyocytes does not result in enhanced protein or DNA synthesis. Enhanced protein and DNA synthesis were observed however when exposing the cells to prorenin combined with angiotensinogen, suggesting that these effects depend on angiotensin generation. Because prorenin binding to M6P/IGFII receptors is followed by internalization and rapid intracellular activation to renin, without subsequent release of renin to the medium,12,13 we reasoned that intracellular angiotensin synthesis might underlie these findings. Such intracellular angiotensin generation will not occur in the absence of prorenin, because neonatal rat cardiomyocytes do not synthesize renin in detectable amounts.25 However, the addition of 10 mmol/L M6P to the medium, which fully blocks prorenin internalization and activation,12,13 did not block the prorenin plus angiotensinogen-induced effects on DNA and protein synthesis. Remarkably, blockade was observed with the AT1 receptor antagonist eprosartan, while the AT2 receptor antagonist PD123319, like M6P, was without effect. In view of the virtual lack of internalization of receptor antagonists,29 the most likely explanation for these findings is that the inherent catalytic activity of prorenin, caused by temporal unfolding of the prosegment, results in extracellular Ang II generation and subsequent AT1 receptor stimulation. In support of this concept, Ang I and Ang II could be detected in nanomolar concentrations in the medium during incubation of the cells with 2 nmol/L prorenin and 150 nmol/L angiotensinogen.

The lack of effect of prorenin binding per se was unexpected, because several groups have reported that binding of M6P-containing glycoproteins to M6P/IGFII receptors results in a cellular response in a G-protein-dependent manner, eg, chemotaxis or increased c-fos expression.19,22 Moreover, binding of renin to human mesangial cells was found to enhance 3H-thymidine incorporation and PAI-1 release, independent of angiotensin generation.9 The receptor mediating the latter effect has not yet been identified and is not necessarily the M6P/IGFII receptor.9 Furthermore, the IGFII analog [Leu27]IGFII, which binds to the M6P/IGFII receptor with equal affinity as IGFII, induced chemotaxis but not DNA synthesis.29,30 Therefore, taken together, it is still very well possible that prorenin binding to M6P/IGFII receptors elicits other cellular responses than protein and DNA synthesis.

The addition of human angiotensinogen to the medium did not result in protein or DNA synthesis. This suggests that neonatal rat cardiomyocytes, like mouse cardiomyocytes,31 do not possess enzymes (eg, cathepsins) capable of cleaving human angiotensinogen into Ang I and des-angiotensinogen. Ang I generation only occurred when combining human prorenin with human angiotensinogen, and this generation was limited to the extracellular compartment. The absence of intracellular Ang I, despite the proteolytic cleavage of prorenin to renin in myocytes, is in agreement with previous studies showing neither binding of angiotensinogen to cardiac
and vascular membrane fractions.1,8 nor angiotensinogen internalization.27 Apparently, the intracellular presence of Ang II in myocytes must be explained on the basis of AT1 receptor-mediated endocytosis,32–34 rather than intracellular Ang II generation. In support of this contention, Ang II was also detected in cell lysates following a 4-hour incubation with 100 nmol/L Ang II. Furthermore, the low cellular Ang II levels during incubation with prorenin plus angiotensinogen (<0.5% of the levels in the medium) also argue against synthesis and/or storage of Ang II in myocytes.23

In the present study, extracellular Ang I generation occurred in a prorenin concentration-dependent manner. At the highest prorenin concentration tested (2 nmol/L), the Ang I levels in the medium reached a steady state within 4 hours. The levels were in the order of 5 nmol/L, which is within the range expected based on the concept that <2% of prorenin is catalytically active.27 We previously reported that, in the absence of serum, Ang I–II conversion by ACE on myocytes is responsible for approximately 50% of Ang I metabolism by neonatal rat cardiomyocytes, and that the Ang I half life under these conditions is 1 hour.25 The Ang II half life is much longer,26 and this may explain why the medium Ang II levels in the present study continued to rise between 1 and 4 hours. Importantly however, the Ang II levels in the medium after 4 hours of prorenin plus angiotensinogen incubation were less than 1 nmol/L, and it is unlikely, in view of the steady-state Ang I levels, that these levels would have become much higher on longer incubation. Yet, despite these relatively low Ang II levels, the effects of prorenin combined with angiotensinogen on protein and DNA synthesis were equal to or stronger than those of 100 nmol/L Ang II. There are several explanations for this apparent discrepancy. First, Ang I–II conversion by ACE may occur in close proximity of AT1 receptors and may thus result in higher Ang II levels in the microenvironment of these receptors than in the medium.35

Second, long-term exposure to low levels of Ang II (as a consequence of continuous Ang II generation) might be more efficient to induce cellular responses than short-term exposure to high levels of Ang II, for instance because the latter results in rapid downregulation of AT1 receptors.26,37 Finally, because neonatal rat cardiomyocytes possess both AT1 and AT2 receptors, Ang II may also stimulate AT2 receptors, and this could counteract the AT1 receptor-induced effects.26,37 It is possible that ACE-dependent local Ang II generation predominantly leads to AT1 receptor activation, because ACE is located in close proximity of AT1 receptors, whereas exogenous Ang II results in equal AT1 and AT2 receptor activation. In agreement with this concept, as in our previous study,26 the Ang II-mediated effect on total cellular protein increased in the presence of PD123319 (Figure 3).

The effects of locally generated and exogenous Ang II on protein and DNA synthesis rate were of modest proportion and exceeded those on total cellular protein and DNA content, suggesting that they may have been counterbalanced, at least in part, by protein and DNA degradation.

In conclusion, the partial catalytic activity of prorenin is responsible for the enhanced protein and DNA synthesis observed in cardiomyocytes during their incubation with prorenin and angiotensinogen. We found no evidence for intracellular angiotensin generation in these cells, nor did prorenin binding to M6P/IGFII receptors per se result in cell proliferation.

Acknowledgment

This study was supported by the Dutch Kidney Foundation, grant no. NSN C99.1874.

References


Prorenin-Induced Myocyte Proliferation: No Role for Intracellular Angiotensin II

Hypertension. 2002;39:573-577
doi: 10.1161/hy0202.103002

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2002 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/39/2/573

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/